| PI3K inhibitors: understanding toxicity mechanisms and management. IB Greenwell, A Ip, JB Cohen Oncology (08909091) 31 (11), 2017 | 143 | 2017 |
| Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow IB Greenwell, CR Flowers, KA Blum, JB Cohen Expert review of anticancer therapy 17 (3), 271-279, 2017 | 63 | 2017 |
| Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy IB Greenwell, AD Staton, MJ Lee, JM Switchenko, DF Saxe, JJ Maly, ... Cancer 124 (11), 2306-2315, 2018 | 52 | 2018 |
| Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period SM Aldrete, CS Kraft, MJ Magee, A Chan, D Hutcherson, AA Langston, ... Transplant Infectious Disease 19 (1), e12649, 2017 | 19 | 2017 |
| Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel JT Romancik, S Goyal, JN Gerson, HJ Ballard, Y Sawalha, DA Bond, ... Blood 138, 1756, 2021 | 14 | 2021 |
| A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma Y Sawalha, S Goyal, JM Switchenko, JT Romancik, M Kamdar, ... Blood advances 7 (13), 2983-2993, 2023 | 9 | 2023 |
| Outcomes of patients with relapsed mantle cell lymphoma treated with venetoclax: a multicenter retrospective analysis Y Sawalha, S Goyal, JM Switchenko, JT Romancik, M Kamdar, ... Blood 136, 4-6, 2020 | 9 | 2020 |
| Treatment patterns and outcomes of patients with CNS involvement of blastic plasmacytoid dendritic cell neoplasm (BPDCN) JA Davis, DA Rizzieri, AA Lane, J Taylor, MS Faisal, S Vasu, D Soong, ... Leukemia & lymphoma 63 (11), 2757-2759, 2022 | 7 | 2022 |
| Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study N Epperla, RL Welkie, P Torka, G Shouse, R Karmali, L Shea, ... Journal of Hematology & Oncology 16 (1), 49, 2023 | 6 | 2023 |
| Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN). IB Greenwell, J Davis, H Li, D Soong, J Taylor, AA Lane, D Rizzieri Journal of Clinical Oncology 39 (15_suppl), e19043-e19043, 2021 | 6 | 2021 |
| Impact of detectable monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: a multicenter cohort study N Epperla, Q Zhao, R Karmali, P Torka, L Shea, TS Oh, ... Blood Advances 7 (17), 5038-5046, 2023 | 4 | 2023 |
| Transplant and chimeric antigen receptor T-cell therapies in elderly patients with lymphoma, a narrative review IB Greenwell, PB Dahi Annals of Lymphoma 6, 2022 | 4 | 2022 |
| Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study N Epperla, Q Zhao, SM Chowdhury, L Shea, TK Moyo, N Reddy, J Sheets, ... Journal of Hematology & Oncology 15 (1), 96, 2022 | 4 | 2022 |
| When to use stem cell transplant in mantle cell lymphoma IB Greenwell, JB Cohen Expert Review of Hematology 12 (4), 207-210, 2019 | 4 | 2019 |
| Risk stratification of untreated mantle cell lymphoma patients using MIPI, Ki67 proliferative index and cytogenetics AD Staton, IB Greenwell, JM Switchenko, J Maly, K Blum, NS Grover, ... Blood 128 (22), 1785, 2016 | 4 | 2016 |
| Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Bruton's Tyrosine Kinase Inhibitor Therapy Y Wang, MC Larson, SR Hwang, A Kumar, A Joseph, BT Hill, TR Brooks, ... Blood 142, 300, 2023 | 3 | 2023 |
| Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data SP Iyer, SR Ayyappan, IB Greenwell, WS Kim, ST Lee, JS Kim, WS Lee, ... Blood 142, 3072, 2023 | 2 | 2023 |
| Use of long-term corticosteroids in patients treated with CAR T-cell therapy H Hashmi, M McGann, BI Greenwell Journal of Oncology Pharmacy Practice 29 (2), 473-476, 2023 | 2 | 2023 |
| Postibrutinib relapse outcomes for patients with marginal zone lymphoma N Epperla, Q Zhao, SM Chowdhury, L Shea, TK Moyo, N Reddy, J Sheets, ... Blood advances 7 (1), 88-91, 2023 | 2 | 2023 |
| Fever characteristics and impact on safety and efficacy of chimeric antigen receptor T-cell therapy JA Davis, KJ Gaffney, M McGann, D Smith, K Edwards, E Baldino, ... Clinical Lymphoma Myeloma and Leukemia 23 (1), e14-e18, 2023 | 2 | 2023 |
